A Prospective, Controlled, Randomised, Cross-over Study Investigating the Pharmacokinetic Properties, Surrogate Efficacy and Safety of Octafibrin Compared to Haemocomplettan.Riastap in Subjects With Congenital Fibrinogen Deficiency
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs Fibrinogen (Primary)
- Indications Afibrinogenaemia; Congenital disorders
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Octapharma
- 14 Oct 2015 Status changed from recruiting to completed according to the ClinicalTrials.gov record.
- 01 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Jun 2015, according to ClinicalTrials.gov record.
- 06 Jan 2015 Planned End Date changed from 1 Aug 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov record.